Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase”
dc.contributor.author | Johnson, Taylor K. | |
dc.contributor.author | Bochar, Daniel A. | |
dc.contributor.author | Vandecan, Nathalie M. | |
dc.contributor.author | Furtado, Jessica | |
dc.contributor.author | Agius, Michael P. | |
dc.contributor.author | Phadke, Sameer | |
dc.contributor.author | Soellner, Matthew B. | |
dc.date.accessioned | 2022-12-05T16:38:35Z | |
dc.date.available | 2023-12-05 11:38:33 | en |
dc.date.available | 2022-12-05T16:38:35Z | |
dc.date.issued | 2022-11-14 | |
dc.identifier.citation | Johnson, Taylor K.; Bochar, Daniel A.; Vandecan, Nathalie M.; Furtado, Jessica; Agius, Michael P.; Phadke, Sameer; Soellner, Matthew B. (2022). "Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase”." Angewandte Chemie 134(46): n/a-n/a. | |
dc.identifier.issn | 0044-8249 | |
dc.identifier.issn | 1521-3757 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175174 | |
dc.description.abstract | Manley and co-workers provide data demonstrating that, at super-pharmacological concentrations (300 μM), a ternary complex between Abl, asciminib, and ATP-competitive inhibitors is possible. The work in our manuscript concerns the interplay of asciminib (and GNF-2) with ATP-competitive inhibitors at pharmacologically relevant concentrations (Cmax=1.6–3.7 μM for asciminib). Manley and co-workers do not question any of the studies that we reported, nor do they provide explanations for how our work fits into their preferred model. Herein, we consider the data presented by Manley and co-workers. In addition, we provide new data supporting the findings in our Communication. Asciminib and ATP-competitive inhibitors do not simultaneously bind Abl at pharmacologically relevant concentrations unless the conformation selectivity for both ligands is matched.At pharmacologically relevant concentrations, asciminib and clinical adenosine triphosphate (ATP) kinase inhibitors cannot simultaneously bind to Abl kinase. Manley and co-workers correspond that at saturating concentrations (i.e., concentrations that are not achievable in a human), asciminib and dasatinib can simultaneously bind to Abl kinase. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Antagonism | |
dc.subject.other | Asciminib | |
dc.subject.other | Kinase | |
dc.title | Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase” | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Chemical Engineering | |
dc.subject.hlbsecondlevel | Chemistry | |
dc.subject.hlbsecondlevel | Materials Science and Engineering | |
dc.subject.hlbtoplevel | Engineering | |
dc.subject.hlbtoplevel | Science | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175174/1/ange202209518-sup-0001-misc_information.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175174/2/ange202209518.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175174/3/ange202209518_am.pdf | |
dc.identifier.doi | 10.1002/ange.202209518 | |
dc.identifier.source | Angewandte Chemie | |
dc.identifier.citedreference | H. Huang, R. Zhao, B. M. Dickson, R. D. Skeel, C. B. Post, J. Phys. Chem. B 2012, 116, 4465 – 4475. | |
dc.identifier.citedreference | X. Wang, A. Roy, A. Hochhaus, H. M. Kantarjian, T.-T. Chen, N. P. Shah, Clin. Pharmacol. 2013, 5, 85 – 97. | |
dc.identifier.citedreference | A. Brown, Int. J. Mol. Sci. 2009, 10, 3457 – 3477. | |
dc.identifier.citedreference | D. Li, L. Chen, R. Wang, R. Liu, G. Ge, Anal. Chem. 2017, 89, 7130 – 7138. | |
dc.identifier.citedreference | T. P. Hughes, M. J. Maure, J. E. Cortes, et al., N. Engl. J. Med. 2019, 381, 2315 – 2326. | |
dc.identifier.citedreference | F. J. Adrián, Q. Ding, T. Sim, et al., Nat. Chem. Biol. 2006, 2, 95 – 102. | |
dc.identifier.citedreference | T.-C. Chou, Pharmacol. Rev. 2006, 58, 621 – 681. | |
dc.identifier.citedreference | T. K. Johnson, D. A. Bochar, N. M. Vandecan, J. Furtado, M. P. Agius, S. Phadke, M. B. Soellner, Angew. Chem. Int. Ed. 2021, 60, 20196 – 20199; Angew. Chem. 2021, 133, 20358 – 20361. | |
dc.identifier.citedreference | F. E. Kwarcinski, K. R. Brandvold, S. Phadke, O. M. Beleh, T. K. Johnson, J. L. Meagher, M. A. Seeliger, J. A. Stuckey, M. B. Soellner, ACS Chem. Biol. 2016, 11, 1296 – 1304. | |
dc.identifier.citedreference | M. P. Agius, K. S. Ko, T. K. Johnson, F. E. Kwarcinski, S. Phadke, E. J. Lachacz, M. B. Soellner, ACS Chem. Biol. 2019, 14, 1556 – 1563. | |
dc.identifier.citedreference | M. A. Seeliger, B. Nagar, F. Frank, X. Cao, M. N. Henderson, J. Kuriyan, Structure 2007, 15, 299 – 311. | |
dc.identifier.citedreference | B. J. Druker, M. Talpaz, D. J. Resta, et al., N. Engl. J. Med. 2001, 344, 1031 – 1037. | |
dc.identifier.citedreference | L. Skora, J. Mestan, D. Fabbro, W. Jahnke, S. Grzsiek, Proc. Natl. Acad. Sci. USA 2013, 110, E4437 – E4445. | |
dc.identifier.citedreference | Asciminib (SCEMBLIX®) prescribing information, Reference ID: 4880647, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf (accessed June 29, 2022). | |
dc.identifier.citedreference | A. B. Patel, T. O’Hare, M. W. Deininger, Hematol. Oncol. Clin. North Am. 2017, 31, 589 – 612. | |
dc.identifier.citedreference | C. A. Eide, M. S. Zabriskie, S. L. S. Stevens, et al., Cancer Cell 2019, 36, 431 – 443. | |
dc.identifier.citedreference | H. J. G. Lindstrom, R. Friedman, BMC Cancer 2020, 20, 397. | |
dc.identifier.citedreference | J. D. Vasta, C. R. Corona, J. Wilkinson, et al., Cell Chem. Biol. 2018, 25, 206 – 214. | |
dc.identifier.citedreference | Cancer Dependency Map, https://depmap.org/portal/cell line/ACH-000983?tab=mutation (accessed June 29, 2022). | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.